Annals of Rheumatic Disease reports on an analysis of lupus (SLE) patients that shows COVID-19 infection rates were similar between those lupus patients who were taking hydroxychloroquine (HCQ) and those not taking HCQ.
Last night's Tuesday Nite Rheumatology featured Dr.
Another lonely locked-down day. Seems like months. Rent is due, phone and EMR fees next week. Loan is pending. Seems impossible to treat complex diseases without touch and only computer screen rapport.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
As many parts of the country are lifting restrictions for businesses and allowing them to re-open, doctors are asking what they should do to keep themselves, their staff, and their patients safe. As rheumatologists, we have vulnerable patients who are at high risk for complications from COV
Severe and fatal outcomes with coronavirus infection are often the result of the downstream damage that follows the viral infection.
Dr. Len Calabrese from the Cleveland Clinic delivers this week's Tuesday Nite Rheumatology Grand Rounds, entitled "IL-6 in Health and Disease: Where Rheumatology Meets COVID-19".
Hydroxychloroquine has been a dominant news item since the start of the COVID-19 crisis, with a great deal of misconceptions by those who don't know or use or take the drug. HCQ leaped to the headlines on March 19th when President Trump endorsed the drug as being “approved” by FDA.
On April 26, 2020 the American College of Rheumatology (ACR) published a guidance paper to assist rheumatologists and rheumatology health professionals in assessing the need for urgent or face-to-face medical care versus virtual or telehealth patient care. The driving principals being
JAMA Cardiology reports the risk of QT (QTc) prolongation when hydroxychloroquine (HCQ) was given to hospitalized patients with coronavirus disease 2019 (COVID-19), especially when given with azithromycin.
The Annals of Rheumatic Disease has published the preliminary recommendations of the German Society of Rheumatology for the management of Inflammatory rheumatic diseases patients during the SARS-CoV-2/Covid-19 pandemic.
The world has been turned upside down in the last 6 weeks. Medicine and rheumatology have certainly changed – a frightening experience for Chicken Little, a disaster for the pessimist, a challenge for the pragmatist and an opportunity for the optimists amongst us.
Links:
Akhil Sood MD @AkhilSoodMD ( View Tweet )
Akhil Sood MD @AkhilSoodMD ( View Tweet )
TheDaoIndex @KDAO2011 ( View Tweet )
